Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Priorities for CMV vaccine development.

Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, Plotkin SA.

Vaccine. 2013 Dec 17;32(1):4-10. doi: 10.1016/j.vaccine.2013.09.042. Epub 2013 Oct 13. Review.

2.

The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.

McCormick AL, Mocarski ES.

Cell Mol Immunol. 2015 Mar;12(2):170-9. doi: 10.1038/cmi.2014.120. Epub 2014 Dec 29. Review.

3.

Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections.

Permar SR, Schleiss MR, Plotkin SA.

J Virol. 2018 Mar 14;92(7). pii: e00030-18. doi: 10.1128/JVI.00030-18. Print 2018 Apr 1. Review.

4.

Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection.

Pass RF, Burke RL.

Semin Pediatr Infect Dis. 2002 Jul;13(3):196-204. Review.

PMID:
12199616
5.

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT.

Lancet Infect Dis. 2012 Apr;12(4):290-9. doi: 10.1016/S1473-3099(11)70344-9. Epub 2012 Jan 10. Erratum in: Lancet Infect Dis. 2012 Apr;12(4):266.

6.

Vaccine Development for Cytomegalovirus.

Inoue N, Abe M, Kobayashi R, Yamada S.

Adv Exp Med Biol. 2018;1045:271-296. doi: 10.1007/978-981-10-7230-7_13. Review.

PMID:
29896672
7.

Development of a cytomegalovirus vaccine: lessons from recent clinical trials.

Gonczol E, Plotkin S.

Expert Opin Biol Ther. 2001 May;1(3):401-12. Review.

PMID:
11727514
8.

Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Schleiss MR, Choi KY, Anderson J, Mash JG, Wettendorff M, Mossman S, Van Damme M.

Vaccine. 2014 May 13;32(23):2756-62. doi: 10.1016/j.vaccine.2013.07.010. Epub 2013 Jul 16.

9.

Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection.

Lanzieri TM, Bialek SR, Ortega-Sanchez IR, Gambhir M.

Vaccine. 2014 Jun 24;32(30):3780-6. doi: 10.1016/j.vaccine.2014.05.014. Epub 2014 May 14.

10.

A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.

Hogea C, Dieussaert I, Van Effelterre T, Guignard A, Mols J.

Hum Vaccin Immunother. 2015;11(7):1788-802. doi: 10.1080/21645515.2015.1016665.

11.

What family doctors know about congenital CMV: a regional survey in Iran.

Hosseinzadeh Adli A, Karami C, Baghban Rahimi S, Mirarab A, Tabarraei A.

Ital J Pediatr. 2018 Mar 1;44(1):31. doi: 10.1186/s13052-018-0470-4.

12.

Vaccines for cytomegalovirus.

Bernstein DI.

Infect Disord Drug Targets. 2011 Oct;11(5):514-25.

PMID:
22309618
13.

Immunization to prevent congenital cytomegalovirus infection.

Adler SP.

Br Med Bull. 2013;107:57-68. doi: 10.1093/bmb/ldt023. Epub 2013 Aug 16. Review.

PMID:
23954939
14.

Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.

Van Craenenbroeck AH, Smits EL, Anguille S, Van de Velde A, Stein B, Braeckman T, Van Camp K, Nijs G, Ieven M, Goossens H, Berneman ZN, Van Tendeloo VF, Verpooten GA, Van Damme P, Cools N.

Transplantation. 2015 Jan;99(1):120-7. doi: 10.1097/TP.0000000000000272.

15.

Cytomegalovirus Vaccines: Current Status and Future Prospects.

Anderholm KM, Bierle CJ, Schleiss MR.

Drugs. 2016 Nov;76(17):1625-1645. Review.

16.

Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Swanson EC, Gillis P, Hernandez-Alvarado N, Fernández-Alarcón C, Schmit M, Zabeli JC, Wussow F, Diamond DJ, Schleiss MR.

Vaccine. 2015 Jul 31;33(32):4013-8. doi: 10.1016/j.vaccine.2015.06.019. Epub 2015 Jun 13.

17.

CMV vaccine trial endpoints.

Griffiths PD.

J Clin Virol. 2009 Dec;46 Suppl 4:S64-7. doi: 10.1016/j.jcv.2009.10.003. Epub 2009 Oct 30.

PMID:
19879802
18.
19.

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.

Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee.

Clin Infect Dis. 2004 Jul 15;39(2):233-9. Epub 2004 Jun 25. Review.

PMID:
15307033
20.

Desirability and feasibility of a vaccine against cytomegalovirus.

Griffiths P, Plotkin S, Mocarski E, Pass R, Schleiss M, Krause P, Bialek S.

Vaccine. 2013 Apr 18;31 Suppl 2:B197-203. doi: 10.1016/j.vaccine.2012.10.074. Review.

Supplemental Content

Support Center